Expert Point of View: Heinz-Josef Lenz, MD


Get Permission

Heinz-Josef Lenz, MD

Heinz-Josef Lenz, MD

Heinz-Josef Lenz, MD, of the University of Southern California in Los Angeles, said the results of the ONO-4538 trial were impressive in light of this challenging patient population. “You see a significant benefit in a highly refractory gastric cancer population,” he said.

Dr. Lenz cautioned: “Don’t get stuck on the median, because the median did not give the full benefit. You see a continuous separation of the survival curves, and as you know, the hazard ratio is the combined differences of both curves over the whole course of ­survival—the cumulative effect.”

Future studies should focus on identifying subgroups of patients whose response to nivolumab drove the overall results of ONO-4538, Dr. Lenz said. ■

Disclosure: Dr. Lenz reported no potential conflicts of interest.


Related Articles

Nivolumab, as Salvage, Improves Overall Survival in Gastric Cancer


These results indicate that nivolumab could be a new treatment option for patients with heavily pretreated advanced gastric cancer and also provide a strong rationale to explore nivolumab in earlier lines of treatment.
— Yoon-Koo Kang, MD

Gastric cancer can...


Advertisement

Advertisement



Advertisement